Michelle Dunk

Michelle Dunk

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in Clinical Nutrition
Verified
Journal Article
Closed access
HDHuiying Da
Huiying Da
RYRongrong Yang
Rongrong Yang
JLJiaxin Liang
Jiaxin Liang
JWJiao Wang
Jiao Wang
WYWenzhe Yang
Wenzhe Yang
WXWeili Xu
Weili Xu

4 April 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MDMichelle Dunk
Michelle Dunk
SRStephen R. Rapp
Stephen R. Rapp
KHKathleen M. Hayden
Kathleen M. Hayden
MEMark A. Espeland
Mark A. Espeland
RCRamon Casanova
Ramon Casanova
IDIra Driscoll
Ira Driscoll
INTRODUCTION: Apolipoprotein E4 (APOE4) carriers’ tendency toward hypercholesterolemia may contribute to Alzheimer's disease (AD) risk through oxysterols, which traverse the blood‐brain barrier.METHODS: Relationships between baseline plasma oxysterols, APOE status, serum lipids, and cognitive impairment risk were examined in 328 postmenopausal women from the Women's Health Initiative Memory Study. Women were followed for 25 years or until incident dementia or cognitive impairment.RESULTS: Levels of 24(S)‐hydroxycholesterol (24‐OHC), 27‐hydroxycholesterol (27‐OHC), and 24‐OHC/27‐OHC ratio did not differ by APOE status (p’s > 0.05). Higher 24‐OHC and 27‐OHC were associated with higher total, low density lipoprotein (LDL), non‐high density lipoprotein (HDL), remnant, LDL/HDL, and total/HDL cholesterol and triglycerides (p’s < 0.05). Higher 24‐OHC/27‐OHC was associated with greater dementia risk (hazard ratio = 1.51, 95% confidence interval:1.02‐2.22), which interaction analyses revealed as significant for APOE3 and APOE4+, but not APOE2+ carriers.DISCUSSION: Less favorable lipid profiles were associated with higher oxysterol levels. A higher ratio of 24‐OHC/27‐OHC may contribute to dementia risk in APOE3 and APOE4+ carriers.

4 October 2024 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
MDMichelle Dunk
Michelle Dunk
IDIra Driscoll
Ira Driscoll
MEMark A Espeland
Mark A Espeland
Kathleen HaydenKathleen Hayden
Kathleen Hayden
SLSimin Liu
Simin Liu
JMJoAnn E Manson
JoAnn E Manson
Background: The apolipoprotein E (APOE) ε4 allele, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD) are well-established risk factors for dementia. Relationships between APOE and incidence of T2DM and CVD are not fully understood but may shed light on the mechanisms underlying dementia pathogenesis. Methods: Postmenopausal women (N = 6 795) from the Women’s Health Initiative hormone therapy clinical trial with APOE genotyping and no prior diagnosis of T2DM or CVD were included. We examined associations of APOE status (APOE2+ [ε2/ε2, ε2/ε3], APOE3 [ε3/ε3], and APOE4+ [ε4/ε4, ε3/ε4] carriers) with incidence of T2DM, coronary heart disease, stroke, and total CVD events using Cox regression. CVD outcomes were examined in baseline non-statin users and adjusted for statin initiation over follow-up to account for possible confounding by statins. Results: Among all participants (mean age 66.7 ± 6.5 years, 100% non-Hispanic White), 451 (6.6%) were using statins at baseline. Over the follow-up (mean 14.9 and 16.0 years for T2DM and CVD, respectively), 1 564 participants developed T2DM and 1 578 developed CVD. T2DM incidence did not differ significantly by APOE status (ps ≥ .09). Among non-statin users, APOE4+ had higher incidence of total CVD (hazard ratio [95% confidence interval] = 1.18 [1.02–1.38], p = .03) compared with APOE3 carriers, but risks for coronary heart disease (1.09 [0.87–1.36], p = .47) and stroke (1.14 [0.91–1.44], p = .27) were not significantly elevated when examined individually. CVD outcomes did not differ between APOE2+ and APOE3 carriers (ps ≥ 0.11). Conclusions: T2DM risk did not differ by APOE status among postmenopausal women, but APOE4+ carriers not using statins had an increased risk of total CVD events.

27 October 2025 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MDMichelle Dunk
Michelle Dunk
HHHuijie Huang
Huijie Huang
JWJiao Wang
Jiao Wang
ADAbigail Dove
Abigail Dove
SSSakura Sakakibara
Sakura Sakakibara
WXWeili Xu
Weili Xu
Pro-inflammatory diets are associated with cognitive decline and dementia, but their impact on brain aging is unclear. We investigated the association between a pro-inflammatory diet and brain age, taking into account age, genetic risk for dementia, and systemic inflammation. UK Biobank participants (N = 21,473) aged 40–70 years and free of neurological disorders were included. The Dietary Inflammatory Index (DII) was calculated from participants’ average intake of 31 nutrients, assessed up to five times via 24-h recalls. Participants were categorized into four DII groups (group 1, anti-inflammatory, DII < −2; group 2, DII −2 to < 0; group 3, DII 0 to < 2; group 4, DII ≥ 2), with group 4 reflecting the most pro-inflammatory diet. Brain age was estimated using a machine learning model based on 1079 structural and functional MRI measures, obtained approximately 9 years after baseline. We calculated brain age gap (BAG; brain age minus chronological age), where BAG > 0 reflects a biologically older brain than chronological age. An Alzheimer’s disease polygenic risk score (PRS AD ), APOE 4 status, and a composite score of systemic inflammation (INFLA-score) were determined from baseline blood samples. More pro-inflammatory diets were associated with increasingly greater BAG, with advanced brain age by $$\widehat{\upbeta }$$ =0.50 [95% CI 0.20, 0.80] years among those in group 4. There were no interactions between DII and age, PRS AD , or APOE 4 in relation to BAG, but associations were stronger among adults ≥ 60 years. INFLA-score mediated 8% of the DII-BAG association. These findings suggest that a pro-inflammatory diet may accelerate brain aging, especially in older adults.

6 November 2025 in Journal of Lipid Research
Verified
Journal Article
Open access
MDMichelle Dunk
Michelle Dunk
LDLjerka Delac
Ljerka Delac
SRStephen R. Rapp
Stephen R. Rapp
IDIra Driscoll
Ira Driscoll
MLMaria Latorre-Leal
Maria Latorre-Leal
SMSilvia Maioli
Silvia Maioli
Women face a higher lifetime risk of developing neurodegenerative diseases such as Alzheimer's disease (AD) and related dementia (ADRD). The menopausal transition, characterized by a decline in estrogen levels, may affect cholesterol metabolism and neurodegenerative processes. Oxysterols, oxidized cholesterol derivatives, play a role in these pathways, with 24(S)-hydroxycholesterol (24HC) reflecting brain cholesterol turnover and 27-hydroxycholesterol (27HC) linked to systemic cholesterol metabolism. We investigated associations of plasma oxysterols with circulating sex hormones and characteristics of reproductive history in 1,974 postmenopausal women with no history of dementia from the Women's Health Initiative, taking into account APOE4 status and cholesterol-lowering medication. We found that higher levels of bioavailable estradiol were associated with higher 24HC and 27HC levels, and higher estrone was associated with higher 24HC (all p-values < 0.05). Associations of estradiol with 24HC and 27HC were stronger among those not using cholesterol medication and APOE4 carriers, with a significant interaction between 27HC and APOE4 in relation to 27HC (p for interaction = 0.04). Having an older age at menopause was associated with lower 24HC among those taking cholesterol medication (p for interaction = 0.03). Our findings suggest that 24HC and 27HC may be proxy biomarkers of neuronal health and estrogen status in postmenopausal women. The stronger associations between estradiol and oxysterols among APOE4 carriers and those not using cholesterol-lowering medication suggest the need to account for hormonal, genetic, and pharmacological factors when evaluating neurodegenerative risk. Longitudinal studies are warranted to further investigate oxysterols as potential early biomarkers of ADRD risk.

9 October 2025 in JACC: Advances
Verified
Journal Article
Open access
MDMichelle Dunk
Michelle Dunk
ADAbigail Dove
Abigail Dove
JWJiao Wang
Jiao Wang
SSSakura Sakakibara
Sakura Sakakibara
ACAdrián Carballo-Casla
Adrián Carballo-Casla
WXWeili Xu
Weili Xu
Cardiometabolic diseases (CMDs; heart disease, stroke, and type 2 diabetes) are associated with dementia risk, but whether a healthy plant-based diet and other lifestyle behaviors can mitigate this risk is unclear. The purpose of this study was to investigate joint associations of CMDs, plant-based diet quality, and other lifestyle behaviors with dementia risk. Dementia-free UK Biobank participants aged ≥55 years with two or more 24-hour dietary recalls were included (N = 71,648). The plant-based diet index (PDI), healthful PDI (hPDI), and unhealthful PDI (uPDI) were calculated according to consumption of 17 food groups. Prevalent CMDs and incident dementia were determined from medical records. A healthy lifestyle beyond diet was defined as never smoking, nonheavy alcohol drinking, and high physical activity. Dementia risk was estimated using Cox regression. A total of 9,656 (13.5%) participants had at least 1 CMD at baseline. After a median of 12.5 years, 825 (1.2%) participants developed dementia. Baseline CMDs were associated with significantly increased risk of dementia (HR: 1.90 [95% CI: 1.53-2.35]). Dementia risk associated with CMDs was reduced among those with high hPDI (HR: 0.39 [95% CI: 0.20-0.74]) and increased for those with high uPDI (HR: 3.24 [95% CI: 1.64-6.40]). The risk of dementia among participants with CMDs and low hPDI was attenuated in the presence of other healthy lifestyle behaviors (HR: 1.47 [95% CI: 0.34-6.36]). Dementia incidence among adults with CMDs differed substantially according to plant-based diet quality. Additional healthy lifestyle behaviors were associated with significant mitigation of dementia risk only in the presence of low hPDI.